• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Individuals at high risk for multiple myeloma may benefit from novel screening technique

by | Dec 11, 2021 | Uncategorized

Source: Healio News A novel high-sensitivity screening approach led to detection of monoclonal gammopathy of undetermined significance at significantly higher rates than conventional methods among people at high risk for multiple myeloma, study results showed.The...

Dose Reduction of Xpovio Improves Safety and Optimizes Patient Outcomes in Myeloma

by | Dec 10, 2021 | Uncategorized

Source: Cure Today articles In recent trial results, a dose reduction of Xpovio (selinexor) was associated with longer progression-free survival and duration of response while also reducing side effects in patients with multiple myeloma. Read More

The ‘eharmony of immunotherapy’: Bispecific T-cell engagers vs. CAR-T for multiple myeloma

by | Dec 3, 2021 | Uncategorized

Source: Healio News Bispecific T-cell engagers have induced impressive response rates among patients with relapsed or refractory multiple myeloma enrolled in early clinical trials.The durability of this novel immunotherapy compared with chimeric antigen receptor...

FDA approves Kyprolis regimen for relapsed or refractory multiple myeloma

by | Dec 1, 2021 | Uncategorized

Source: Healio News The FDA approved a combination of carfilzomib, a subcutaneous formulation of daratumumab, and dexamethasone for certain patients with relapsed or refractory multiple myeloma.The expansion of the carfilzomib (Kyprolis, Amgen) prescribing information...

FDA Approves Darzalex Faspro Plus Kyprolis and Dexamethasone for Myeloma Treatment

by | Dec 1, 2021 | Uncategorized

Source: Cure Today articles The FDA approved the three-drug regimen of Darzalex Faspro, Kyprolis and dexamethasone for patients with pretreated relapsed/refractory multiple myeloma. Read More

Three-Drug Combo Meets ‘Gold Standard’ Overall Survival for Older Patients with Multiple Myeloma

by | Nov 23, 2021 | Uncategorized

Source: Cure Today articles Darzalex plus Revlimid and dexamethasone may be the preferred option to treat older patients with multiple myeloma who are ineligible for stem-cell transplant. Read More
« Older Entries
Next Entries »

Recent Content

  • A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast
  • Talquetamab and Teclistamab Achieve Deep, Durable Responses in Patients With Relapsed, Refractory Multiple Myeloma
  • Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study
  • Fixed-Dose Subcutaneous Sarclisa Combo is Non-Inferior to IV Sarclisa in R/R Myeloma
  • Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
  • Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
  • IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab
  • Combination induces durable responses in advanced multiple myeloma
  • Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes
  • Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT